AltMountain

Integral Health Asset Management, LLC

New York, NY · CRD 301987
Hedge fund manager

Integral Health Asset Management, LLC is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $1.9 billion in regulatory assets under management. Its private funds, of all types, hold $60.2 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +14.8% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +65.0% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$1.9 billionForm ADV Item 5.F
Gross assets of private funds
$60.2 millionAll private fund types, Form ADV
Hedge funds managed
11 private funds in total
Employees
12Form ADV Item 5.A
Registration
SEC-registered adviserCRD 301987
Latest Form ADV
03/26/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+14.8%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+65.0%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$2.4 billion89 positions, 2026-06-30
$92$129$165Q3 2024Q1 2025Q3 2025Q1 202613F est. $165S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+17.9%+14.8%
Q1 2026-2.6%-4.6%
Q4 2025+15.2%+2.4%
Q3 2025+26.3%+7.8%
Q2 2025+7.1%+10.4%
Q1 2025-5.0%-4.5%
Q4 2024-8.5%+2.1%
Q3 2024+6.1%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

The 50 largest of 96 share positions ($1,635,097,325) reported by Integral Health Asset Management, LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Revolution Medicines Inc7.97%
  • Insmed Inc7.89%
  • Edgewise Therapeutics Inc5.96%
  • Cytokinetics Inc4.43%
  • Merck & Co Inc4.00%
  • Scholar Rock Hldg Corp3.71%
  • Centene Corp Del2.85%
  • Axsome Therapeutics Inc.2.82%
  • Vera Therapeutics Inc1.97%
  • Amgen Inc1.93%
StockValue% of 13F portfolioSharesShares vs prior quarter
Revolution Medicines Inc$130,340,1007.97%1,000,000-33.33%
Insmed Inc$128,978,2007.89%1,600,000Unchanged
Edgewise Therapeutics Inc$97,440,0005.96%2,400,000+20.00%
Cytokinetics Inc$72,501,0004.43%1,600,000Unchanged
Merck & Co Inc$65,389,5004.00%450,000+28.57%
Scholar Rock Hldg Corp$60,641,6003.71%1,255,000+67.33%
Centene Corp Del$46,590,0002.85%750,000+150.00%
Axsome Therapeutics Inc.$46,097,5002.82%250,000-16.67%
Vera Therapeutics Inc$32,290,0001.97%1,500,000-14.29%
Amgen Inc$31,613,2501.93%75,000New
Lifestance Health Group Inc$31,278,0001.91%2,600,000-13.33%
Regeneron Pharmaceuticals$30,330,8001.85%40,000Unchanged
Tenet Healthcare Corp$23,000,4001.41%90,000-45.45%
Biogen Inc$22,588,0001.38%100,000Unchanged
Tango Therapeutics Inc$22,455,0001.37%1,000,000Unchanged
Cardinal Health Inc$22,250,0001.36%100,000-66.67%
CVS Health Corp$21,422,5001.31%500,000-54.55%
Neurocrine Biosciences Inc$21,276,0001.30%150,000Unchanged
Vertex Pharmaceuticals Inc$20,912,4001.28%40,000Unchanged
Oric Pharmaceuticals Inc$20,205,0001.24%1,700,000-10.53%
Bridgebio Pharma Inc$19,740,0001.21%300,000+9.09%
Incyte Corp$19,416,0001.19%160,000New
Definium Therapeutics Inc$19,030,0001.16%500,000-9.09%
Brightspring Health Svcs Inc$18,443,7501.13%325,000-40.91%
Beone Medicines LTD$18,297,0001.12%50,000New
Roivant Sciences LTD$18,285,0001.12%2,000,000Unchanged
LB Pharmaceuticals Inc$18,038,6001.10%470,000+213.33%
Becton Dickinson & Co$17,900,0001.09%100,000New
Boston Scientific Corp$17,460,0001.07%400,000-55.56%
Edwards Lifesciences Corp$17,264,0001.06%200,000-68.00%
Erasca Inc$16,565,8001.01%1,130,000+13.00%
Alkermes PLC$15,195,0000.93%375,000+275.00%
Medtronic PLC$15,100,7500.92%175,000-12.50%
Glaukos Corp$14,777,1000.90%90,000-40.00%
Encompass Health Corp$14,578,8000.89%120,000New
Novartis AG$14,257,0000.87%100,000-50.00%
Absci Corporation$14,001,0000.86%1,300,000+62.50%
Quest Diagnostics Inc$12,818,8500.78%55,000-72.50%
Alto Neuroscience Inc$12,765,0000.78%500,000Unchanged
Madrigal Pharmaceuticals Inc$12,599,0000.77%25,000Unchanged
Bristol-myers Squibb Co$12,480,0000.76%200,000New
Uniqure NV$12,080,0000.74%500,000-44.44%
Rhythm Pharmaceuticals Inc$11,901,8750.73%250,000-54.55%
Teva Pharmaceutical Inds LTD$11,880,0000.73%300,000New
Travere Therapeutics Inc$11,776,0000.72%200,000-46.67%
Praxis Precision Medicines I$11,649,2000.71%40,000Unchanged
Livanova PLC$11,475,0000.70%150,000New
Waters Corp$10,984,7500.67%25,000-37.50%
Surrozen Inc$10,458,5000.64%325,000New
Inspire Med SYS Inc$10,404,0000.64%150,000+50.00%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 39 new positions, 32 sold out, 12 increased, 26 reduced and 19 unchanged.

Number of positions (a count, not dollars)

  • New positions39
  • Increased12
  • Unchanged19
  • Reduced26
  • Sold out32

New positions

StockValueShares
Amgen Inc$31,613,25075,000
Incyte Corp$19,416,000160,000
Beone Medicines LTD$18,297,00050,000
Becton Dickinson & Co$17,900,000100,000
Encompass Health Corp$14,578,800120,000
Bristol-myers Squibb Co$12,480,000200,000
Teva Pharmaceutical Inds LTD$11,880,000300,000
Livanova PLC$11,475,000150,000
Surrozen Inc$10,458,500325,000
Tyra Biosciences Inc$9,950,850455,000
Thermo Fisher Scientific Inc$9,450,70014,000
Ovid Therapeutics Inc$8,715,0003,500,000
Cooper Cos Inc$8,479,500150,000
Climb Bio Inc$8,029,000700,000
Attovia Therapeutics Inc$7,713,000450,000
Alnylam Pharmaceuticals Inc$7,402,20030,000
Faeth Therapeutics Inc$7,137,600240,000
Guardant Health Inc$7,134,40040,000
TG Therapeutics Inc$6,972,500125,000
Ionis Pharmaceuticals Inc$6,697,500150,000

Sold out

StockValue at Jun 30, 2026Shares held then
Alignment Healthcare Inc$47,620,0002,000,000
Abbott Laboratories$36,296,000400,000
Unitedhealth Group Inc$35,328,55085,000
Novo-nordisk A S$28,764,000600,000
Lantheus Hldgs Inc$21,078,600190,000
Elevance Health Inc Formerly$19,336,50050,000
Eli Lilly & Co$17,991,45015,000
Arrowhead Pharmaceuticals In$16,302,000200,000
Envista Holdings Corporation$15,810,000600,000
Livanova PLC$14,801,400180,000
Forte Biosciences Inc$14,343,750675,000
Xenon Pharmaceuticals Inc$12,072,000200,000
Ascendis Pharma A/s$12,002,40045,000
Acadia Healthcare Company In$11,812,000400,000
Irhythm Holdings Inc$10,705,50090,000
Integra Lifesciences Hldgs C$9,878,000550,000
Ge Healthcare Technologies I$9,601,500150,000
Bruker Corp$9,027,000150,000
Cencora Inc$8,489,40030,000
Bioage Labs Inc$7,353,000300,000

Largest increases

StockChange in sharesChangeValue nowShares now
Centene Corp Del+450,000+150.00%$46,590,000750,000
Scholar Rock Hldg Corp+505,000+67.33%$60,641,6001,255,000
Edgewise Therapeutics Inc+400,000+20.00%$97,440,0002,400,000
Merck & Co Inc+100,000+28.57%$65,389,500450,000
LB Pharmaceuticals Inc+320,000+213.33%$18,038,600470,000
Alkermes PLC+275,000+275.00%$15,195,000375,000
Absci Corporation+500,000+62.50%$14,001,0001,300,000
Inspire Med SYS Inc+50,000+50.00%$10,404,000150,000
Regenxbio Inc+400,000+50.00%$9,036,0001,200,000
Erasca Inc+130,000+13.00%$16,565,8001,130,000
Bridgebio Pharma Inc+25,000+9.09%$19,740,000300,000
Kardigan Inc+25,000+12.50%$3,318,750225,000

Largest reductions

StockChange in sharesChangeValue nowShares now
Revolution Medicines Inc-500,000-33.33%$130,340,1001,000,000
Cardinal Health Inc-200,000-66.67%$22,250,000100,000
Edwards Lifesciences Corp-425,000-68.00%$17,264,000200,000
Quest Diagnostics Inc-145,000-72.50%$12,818,85055,000
CVS Health Corp-600,000-54.55%$21,422,500500,000
Boston Scientific Corp-500,000-55.56%$17,460,000400,000
Tenet Healthcare Corp-75,000-45.45%$23,000,40090,000
Rhythm Pharmaceuticals Inc-300,000-54.55%$11,901,875250,000
Novartis AG-100,000-50.00%$14,257,000100,000
Brightspring Health Svcs Inc-225,000-40.91%$18,443,750325,000
Travere Therapeutics Inc-175,000-46.67%$11,776,000200,000
Glaukos Corp-60,000-40.00%$14,777,10090,000
Uniqure NV-400,000-44.44%$12,080,000500,000
Axsome Therapeutics Inc.-50,000-16.67%$46,097,500250,000
Waters Corp-15,000-37.50%$10,984,75025,000
Vera Therapeutics Inc-250,000-14.29%$32,290,0001,500,000
Biohaven LTD-400,000-57.14%$4,005,000300,000
Lifestance Health Group Inc-400,000-13.33%$31,278,0002,600,000
Beam Therapeutics Inc-100,000-33.33%$4,890,000200,000
Oric Pharmaceuticals Inc-200,000-10.53%$20,205,0001,700,000

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (3)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (1)

As reported in the adviser's Form ADV filed Mar 27, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​‌​⁠